Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Cancers (Basel) · 2026 · PMC13024652 · PMID 41899601

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

Moreover, the dose-reduction cohort exhibited a higher median age (72 years; IQR, 68–79) compared with the full-dose cohort (71 years; IQR, 65–77); however, this difference did not reach statistical significance ( p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.